Is alternate daily dose of atorvastatin effective in treating patients with hyperlipidemia? The Alternate Day Versus Daily Dosing of Atorvastatin Study (ADDAS)

American Heart Journal

Volumn 144, Issue 4, 2002, Pages 674-677

  Matalka, Mazen S ^a   Ravnan, Marcus C ^b   Deedwania, Prakash C ^c,d  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b University of the Pacific School of Pharmacy and Health Sciences   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Fresno Program   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST CONTROL; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEALTH CARE COST; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; MALE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK FACTOR; STATISTICAL ANALYSIS;

EID: 0036791192     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-8703(02)00140-0     Document Type: Article

References (11)

1. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
2. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001-9.
3. Shepperd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301-7.
4. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TEXCAPS. JAMA 1998;279:1615-22.
5. Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-57.
6. Nawrocki JW, Weiss SR, Davidson MH, et al. Reduction of LDL cholesterol by 25 to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler Thromb Vasc Biol 1995;15:678-82.
7. Lipitor (atorvastatin calcium) tablet. Data sheet. Morris Plains, NJ: Park Davis, Division of Warner-Lambert Company; 1999.
8. Lea AP, McTavish D. Atorvastatin: a review of its pharmacology and therapeutic potential in the management of hyperlipidemias. Drugs 1997;53:828-47.
9. National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment panel II). Summary of the secand report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II). JAMA 1993;269:3015-23.
10. Friedewald WT, Levy RI, Frederickson DS. Estimation of concentration of low density lipoprotein cholesterol in plasma without the use of preparative ultracentrifuge. Clin Chem 1972;18:499-502.
11. Pearson TA, Laurora I, Chu H, et al. The Lipid Treatment Assessment Project (L-TAP): a multi-center survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med 2000;160:459-67.